Patents by Inventor Kenneth B. Idler

Kenneth B. Idler has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20160237491
    Abstract: The present invention features therapies for the treatment of HCV comprising direct-acting antiviral agents. Preferably, the treatment is administered to an HCV-infected patient who has been tested to determine methylation status of a CpG island within a promoter region of the IL28B gene. In one aspect, the therapies comprise administering one or more direct acting antiviral agents and, optionally ribavirin, to a subject with HCV infection. For example, the therapies comprise administering to the subject effective amounts of therapeutic agent 1, therapeutic agent 2, therapeutic agent 3, an inhibitor of cytochrome P450 (e.g., ritonavir), and/or ribavirin.
    Type: Application
    Filed: November 10, 2014
    Publication date: August 18, 2016
    Inventors: Daniel E. Cohen, Kenneth B. Idler, Jeffrey F. Waring, Emily O. Dumas, Sandeep Dutta
  • Publication number: 20160228496
    Abstract: The present invention features therapies for the treatment of HCV comprising direct-acting antiviral agents. Preferably, the treatment is administered to an HCV-infected patient who has been tested to determine methylation status of a CpG island within a promoter region of the IL28B gene. In one aspect, the therapies comprise administering one or more direct acting antiviral agents and, optionally ribavirin, to a subject with HCV infection. For example, the therapies comprise administering to the subject effective amounts of therapeutic agent 1, therapeutic agent 2, therapeutic agent 3, an inhibitor of cytochrome P450 (e.g., ritonavir), and/or ribavirin.
    Type: Application
    Filed: March 13, 2014
    Publication date: August 11, 2016
    Applicant: AbbVie Inc.
    Inventors: Daniel E. Cohen, Kenneth B. Idler, Jeffrey F. Waring, Emily O. Dumas, Sandeep Dutta
  • Patent number: 6406841
    Abstract: The present invention relates generally to a novel human T-cell lymphotropic, or leukemia, virus type II (HTLV-II) isolate designated NRA. HTLV-IINRA was originally isolated from a patient with atypical hairy cell leukemia. Preliminary restriction analysis of this isolate demonstrated that it differs genetically from the prototypical HTLV-II isolate Mo. HTLV-IINRA proviral molecular clones were obtained and the entire nucleotide sequence of the virus ascertained. The claimed invention is particularly directed toward the gp46 and p21e envelope proteins encoded by the env gene. Methods and kits for the detection of HTLV-II antibodies employing these envelope proteins are also described.
    Type: Grant
    Filed: June 20, 1994
    Date of Patent: June 18, 2002
    Assignee: Abbott Laboratories
    Inventors: Helen H. Lee, Priscilla A. Swanson, Kenneth B. Idler, Joseph D. Rosenblatt, Irvin S. Y. Chen, David W. Golde, Eugene Robertson, John E. Stephens, Emerson W. Chan, Mark H. Buytendorp, Joan E. Johnson, Cheryl T. Motley, Michelle Edwards, Cynthia Tate, Bryan Peterson, Peggy Guidinger
  • Publication number: 20020042045
    Abstract: Compositions including lysates, DNA and amino acid sequences derived from HTLV-IINRA are provided. Assays for detecting HTLV infection that employ the disclosed HTLV-IINRA compositions are also provided. Kits for performing HTLV assays are further provided.
    Type: Application
    Filed: June 20, 1994
    Publication date: April 11, 2002
    Inventors: HELEN H. LEE, PRISCILLA A. SWANSON, KENNETH B. IDLER, JOSEPH D. ROSENBELT, RIVIN S. Y. CHEN, DAVID W. GOLDE, EUGENE ROBERTSON, JOHN E. STEPHENS, EMERSON W. CHAN, MARK H. BUYTENDORP, JOAN E. JOHNSON, CHERYL T. MOTLEY, MICHELLE EDWARDS, CYNTHIA TATE, BRYAN PETERSON, PEGGY GUIDINGER